Rapid Micro Biosystems, Inc. (RPID)
| Market Cap | 91.99M -8.3% |
| Revenue (ttm) | 34.38M +16.0% |
| Net Income | -50.14M |
| EPS | -1.11 |
| Shares Out | 45.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 462,432 |
| Open | 2.000 |
| Previous Close | 1.980 |
| Day's Range | 1.910 - 2.120 |
| 52-Week Range | 1.900 - 4.940 |
| Beta | 1.53 |
| Analysts | Strong Buy |
| Price Target | 8.00 (+298.01%) |
| Earnings Date | May 13, 2026 |
About RPID
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biologics, medical devices, and personal care products in the United States, Switzerland, Germany, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the antiquat... [Read more]
Financial Performance
In 2025, Rapid Micro Biosystems's revenue was $33.59 million, an increase of 19.74% compared to the previous year's $28.05 million. Losses were -$47.12 million, 0.50% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for RPID stock is "Strong Buy." The 12-month stock price target is $8.0, which is an increase of 298.01% from the latest price.
News
Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering
Bain Capital Life Sciences and Armistice Capital are investing approximately $9.8 million, with the potential of up to approximately $32 million in the event the warrants offered in this offering are ...
Rapid Micro Biosystems Q1 Earnings Call Highlights
Rapid Micro Biosystems NASDAQ: RPID reported first-quarter 2026 revenue growth and reaffirmed its full-year outlook, citing momentum in system placements, consumables and recurring revenue, while mana...
Rapid Micro Biosystems reports Q1 EPS (31c), consensus (25c)
Reports Q1 revenue $8.0M, consensus $7.6M. Cash, cash equivalents, short-term investments, and restricted cash were approximately $23M as of March 31. “Our first quarter results reflect strong and con...
Rapid Micro Biosystems Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 11% year-over-year to $8 million, driven by strong system placements and recurring revenue, with record consumables growth and improved product margins. The company reaffirmed its 2026 revenue guidance and continues to expand globally, especially in Asia-Pacific.
Rapid Micro Biosystems Earnings release: Q1 2026
Rapid Micro Biosystems released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Rapid Micro Biosystems Quarterly report: Q1 2026
Rapid Micro Biosystems has published its Q1 2026 quarterly earnings report on May 13, 2026.
Rapid Micro Biosystems Reports First Quarter 2026 Financial Results
LEXINGTON, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation sol...
Rapid Micro Biosystems Slides: Corporate presentation
Rapid Micro Biosystems has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Rapid Micro Biosystems to Announce First Quarter 2026 Financial Results on May 13, 2026
LEXINGTON, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation sol...
Rapid Micro Biosystems Proxy statement: Proxy filing
Rapid Micro Biosystems filed a proxy statement on April 8, 2026, providing details for shareholder voting and corporate governance matters.
Rapid Micro Biosystems Proxy statement: Proxy filing
Rapid Micro Biosystems filed a proxy statement on April 8, 2026, providing details for shareholder voting and corporate governance matters.
Rapid Micro Biosystems Slides: Corporate presentation
Rapid Micro Biosystems has posted slides in relation to its latest quarterly earnings report, which was published on April 8, 2026.
Rapid Micro Biosystems management to meet virtually with Lake Street
Virtual Meeting to be held on April 9-10 hosted by Lake Street.
Rapid Micro Biosystems Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Automation of microbial quality control is driving faster, more reliable pharmaceutical manufacturing, with strong recurring revenue from consumables and services. 2026 guidance targets 16% revenue growth, margin expansion, and significant runway for customer and market penetration, supported by strategic partnerships and operational efficiencies.
Lake Street would buy the weakness in Rapid Micro Biosystems after Q4 report
Lake Street notes that Rapid Micro Biosystems (RPID) reported Q4 revenue in line with its January pre-release and established 2026 revenue guidance of $37M-$41M, compared to the firm’s estimate of…
Rapid Micro Biosystems Earnings Call Transcript: Q4 2025
Q4 revenue grew 37% year-over-year to $11.3M, driven by record system placements and strong consumable growth. 2026 guidance projects $37–$41M revenue, 30–38 system placements, and gross margin expansion to ~20%, supported by cost reductions and strategic partnerships.
Rapid Micro Biosystems Annual report: Q4 2025
Rapid Micro Biosystems has published its Q4 2025 annual report on March 12, 2026.
Rapid Micro Biosystems Earnings release: Q4 2025
Rapid Micro Biosystems released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.
Rapid Micro Biosystems reports Q4 EPS (28c), consensus (23c)
Reports Q4 revenue $11.3M, consensus $10.93M. “We closed 2025 with significant momentum, delivering 20% year-over-year revenue growth,” said Robert Spignesi, President and CEO. “Our performance was hi...
Rapid Micro Biosystems sees FY26 revenue $37M-$41M, consensus $39.9M
For the full year 2026, the Company expects total revenue in the range of $37.0 million to $41.0 million including a range of 30 to 38 Growth Direct system placements…
Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
Reports record fourth quarter 2025 total revenue of $11.3 million , representing 37% growth compared to fourth quarter 2024 Reports full year 2025 total revenue of $33.6 million , representing 20% gr...
Rapid Micro Biosystems announces new multi-system order from Samsung Biologics
Rapid Micro Biosystems (RPID) announced a new multi-system order from Samsung Biologics for its Growth Direct platform. This follow-on order builds on the companies’ existing partnership and supports ...
Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct® Platform
Companies deepen partnership to advance automated, integrated microbiology quality control Companies deepen partnership to advance automated, integrated microbiology quality control
Rapid Micro Biosystems to Participate in KeyBanc Capital Markets Healthcare Forum
LEXINGTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation s...
Rapid Micro Biosystems Transcript: TD Cowen 46th Annual Health Care Conference
Rapid automation of pharmaceutical microbial quality control is driving strong recurring revenue and margin growth, supported by global expansion and a strategic partnership with MilliporeSigma. AI-driven data insights and regulatory trends are expected to accelerate adoption, with significant impact projected from 2026 onward.